Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye ...

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye ...

Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema (DME) has the potential to address significant unmet needs for early…

Oculis Completes Final Patient Visit in Phase 3 DIAMOND Program for DME

Key Takeaways Oculis has completed the final patient visit in its phase 3 DIAMOND trials for OCS-01, with topline results expected in June 2026 OCS-01 is a potential first-in-class, noninvasive eye drop for diabetic macular edema, aiming to reduce reliance on injections  The company is targeting a potential NDA submission in Q4 2026 Oculis announced it has completed the final patient visit in its phase 3 DIAMOND program evaluating OCS-01 eye d…